ImmunAdd Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 2

ImmunAdd General Information

Description

Developer of pharmaceutical ingredients designed to boost immune responses in vaccines and treatments. The company's technology utilizes a proprietary plant cell culture platform to sustainably manufacture saponin-based adjuvants, enabling pharmaceutical manufacturers to enhance vaccine effectiveness and stability while ensuring a secure supply of critical immunomodulators for improved patient care.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 11 Floor.-8, Number 130, Sector. 2, Zhongxiao E. Road
  • Zhongzheng District
  • Taipei
  • Taiwan
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Corporate Office
  • 11 Floor.-8, Number 130, Sector. 2, Zhongxiao E. Road
  • Zhongzheng District
  • Taipei
  • Taiwan

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ImmunAdd Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC 01-Jul-2026 Completed Generating Revenue
To view ImmunAdd’s complete valuation and funding history, request access »

ImmunAdd Patents

ImmunAdd Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2025228754-A1 Adjuvant composition, pharmaceutical composition comprising the same, and method for preventing or treating disease caused by viral infection, bacterial infection, protozoal infection or cancer Pending 29-Feb-2024
US-20250295763-A1 Adjuvant composition, pharmaceutical composition comprising the same, and method for preventing or treating disease caused by viral infection, bacterial infection, protozoal infection or cancer Pending 29-Feb-2024
WO-2025180443-A1 Adjuvant composition, pharmaceutical composition comprising the same, and method for preventing or treating disease caused by viral infection, bacterial infection, protozoal infection or cancer Pending 29-Feb-2024 A61K39/39

ImmunAdd Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bailey Biofund Venture Capital Minority
Diamond Biofund Venture Capital Minority
To view ImmunAdd’s complete investors history, request access »

ImmunAdd FAQs

  • When was ImmunAdd founded?

    ImmunAdd was founded in 2022.

  • Where is ImmunAdd headquartered?

    ImmunAdd is headquartered in Taipei, Taiwan.

  • What industry is ImmunAdd in?

    ImmunAdd’s primary industry is Drug Discovery.

  • Is ImmunAdd a private or public company?

    ImmunAdd is a Private company.

  • What is ImmunAdd’s current revenue?

    The current revenue for ImmunAdd is .

  • Who are ImmunAdd’s investors?

    Bailey Biofund and Diamond Biofund have invested in ImmunAdd.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process